Eric Crombez's most recent trade in Ultragenyx Pharmaceutical Inc. was a trade of 30,246 Stock Ooption (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 30,246 | 30,246 | - | - | Stock Ooption (Right to Buy) | |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 16,813 | 65,244 (0%) | 0% | 0 | Common Stock | |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 14,971 | 80,215 (0%) | 0% | 0 | Common Stock | |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 42.10 per share. | 01 Mar 2025 | 8,945 | 71,922 (0%) | 0% | 42.1 | 376,585 | Common Stock |
Abeona Therapeutics Inc | Eric Crombez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 36,101 | 47,145 (0%) | 0% | 0 | Common Stock | |
Abeona Therapeutics Inc | Eric Crombez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 11,044 | 11,044 (0%) | 0% | 0 | Common Stock | |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.66 per share. | 02 May 2024 | 354 | 48,431 (0%) | 0% | 43.7 | 15,456 | Common Stock |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 44.10 per share. | 18 Apr 2024 | 142 | 48,785 (0%) | 0% | 44.1 | 6,262 | Common Stock |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 34,200 | 34,200 | - | - | Stock Option (Right to Buy) | |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 19,400 | 49,912 (0%) | 0% | 0 | Common Stock | |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 2,351 | 2,351 | - | - | Stock Option (Right to Buy) | |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 53.76 per share. | 01 Mar 2024 | 1,238 | 48,927 (0%) | 0% | 53.8 | 66,555 | Common Stock |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 8,362 | 8,362 | - | - | Stock Option (Right to Buy) | |
Ultragenyx Pharmaceutical ... | Eric Crombez | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 4,658 | 30,512 (0%) | 0% | 0 | Common Stock |